Clinical Trials Sponsored by SecuraBio

Total 26 results

SecuraBio

Completed

A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma (TEMPO)

Indolent Non-Hodgkin Lymphoma

Korea, Republic of, Czechia, United States, United Kingdom, Italy, Poland, Russian Federation, Germany
SecuraBio

Completed

IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study

Healthy Volunteers

Netherlands
SecuraBio

Completed

Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145 (DDI)

Healthy

United States
SecuraBio

Completed

Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects (IPI-145-14)

Hepatic Impairment

United States
SecuraBio

Terminated

Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R)

Follicular Lymphoma

France, Italy, Australia, Poland
SecuraBio

Terminated

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma

United States
SecuraBio

Completed

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Belgium, France, Italy, Spain, United States, Austria, New Zealand, Hungary, Germany, United Kingdom, Australia
SecuraBio

Completed

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Belgium, France, Italy, Spain, United States, Austria, New Zealand, Hungary, United Kingdom, Australia, Germany
SecuraBio

Completed

IPI-145 ADME and Absolute Bioavailability Study

Healthy

Netherlands
SecuraBio

Completed

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145

Healthy

United States
SecuraBio

Completed

A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) (PRIMO)

Peripheral T-cell Lymphoma

United States, United Kingdom, Germany, Italy
SecuraBio

Terminated

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

CD20+ Follicular Lymphoma

Belgium, Italy, United States, Spain, United Kingdom, France
SecuraBio

Completed

A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)

Hematologic Malignancy

United States, Italy
SecuraBio

Completed

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)

Indolent Non-Hodgkin Lymphoma

Belgium, France, Italy, Spain, Canada, United States, Bulgaria, United Kingdom, Hungary, Georgia, Belarus, Czechia
SecuraBio

Withdrawn

Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (BRIO)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
SecuraBio

Terminated

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Lymphoma, Small Lymphocytic | Lymphocytic Leukemia, Chronic

United States, Canada
SecuraBio

Completed

A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone (ASPIRA)

Rheumatoid Arthritis

Poland, Ukraine, Mexico, Bulgaria, Romania, Serbia, New Zealand, Russian Federation, Germany, Hungary, Colombia
SecuraBio

Completed

Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam (DDI)

Healthy

United States
SecuraBio

Completed

A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects

Asthma

Germany, United Kingdom
SecuraBio

Withdrawn

Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Lymphoma

United States
SecuraBio

Terminated

Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL (REAL)

Lymphoma | Lymphoma, Non-Hodgkin | Follicular Lymphoma | Chronic Lymphocytic Leukemia | Lymphoma, Small Lymphocytic

United States
SecuraBio

Withdrawn

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

Follicular Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
SecuraBio

Terminated

A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

Hematologic Malignancies

United States
Washington University School of Medicine
SecuraBio

Recruiting

Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

T-Cell Lymphoma

United States
University of Washington
National Cancer Institute (NCI); SecuraBio

Terminated

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Washington University School of Medicine
National Cancer Institute (NCI); The Foundation for Barnes-Jewish Hospital; S...

Recruiting

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Acute Lymphocytic Leukemia | Non-hodgkin Lymphoma

United States

Clinical Trials Sponsored by SecuraBio

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations